Scroll

About Us

Who We Are

CMed Aesthetics was founded in 2017 by Andrea Malventi and Carlo Michelini with the ambition to build a solid industrial project in the fields of aesthetic medicine, dermatology and plastic surgery.

Operating in a rapidly evolving sector that requires multidisciplinary expertise, strict regulatory compliance and a long-term strategic vision, the company was established with a clear focus on quality, safety and sustainable growth.

From its earliest stages, CMed Aesthetics has positioned itself as a reliable partner for healthcare professionals, institutions and industrial stakeholders, combining scientific rigor, operational reliability and international market awareness.

Our Journey

The early development of CMed Aesthetics was marked by significant investments in know-how, infrastructure and corporate governance.

Over time, the company structured its activities along the entire medical aesthetics value chain, building integrated expertise ranging from the selection and management of medical devices and aesthetic products to regulatory compliance, sterilization processes and scientific support.

CMed Aesthetics has also maintained a constant presence at leading international congresses such as IMCAS, Dubai Derma, AMWC, SIME and Agorà, considering these events strategic opportunities for scientific exchange and international positioning.

Our Mission & Vision

Everything we do is aimed to improve people's wellness and beauty

CMed Aesthetics is driven by an ambitious vision: to contribute to shaping the future of aesthetic medicine.

The company continuously invests in research and development to ensure that its products remain aligned with the most advanced scientific progress. Safety and efficacy represent non-negotiable principles guiding every stage of the company’s activities, responding to the evolving needs of both healthcare professionals and patients.

CMed Aesthetics aims to act as a catalyst for positive change within the industry, promoting innovation and contributing to the definition of new standards of scientific and industrial excellence.

Proprietary Technologies Driving
Our Industrial Identity

A key element of the company’s industrial identity is the development of proprietary technologies, including:

NTS^® (Non Thermal Stress Technology), an innovative sterilization method

Biphasic Technology^®, developed as part of the company’s ongoing commitment to research and innovation

This growth has been built on solid industrial foundations rather than purely commercial dynamics, strengthening the company’s credibility within the global aesthetic medicine market.

The organization operates through structured and certified processes, as demonstrated by the achievement

Certified Processes and International Quality Standards

certificates

ISO 22716

certificates

ISO 13485

certificates

HALAL

An International Presence

Today, CMed Aesthetics represents a mature industrial organization with a clear and recognizable positioning within the Italian and international aesthetic medicine landscape. Headquartered in Pisa, Italy, the company operates in more than 85 countries worldwide, reflecting a strong international vocation developed through operational reliability, product quality and the ability to navigate complex regulatory environments.

our story

The growth of CMed

2017

CMed Founded in 2017: A Vision for Aesthetic Medicine

CMed was founded from the shared vision of two friends who aspired to build a solid industrial venture in the fields of aesthetic medicine, dermatology, and plastic surgery.

2018

BioRePeelCl₃^®: The Innovative Biphasic Chemical Peel

In 2018, the BioRePeelCl₃^® medical device was introduced to the market, revolutionizing the field of chemical peels with its innovative biphasic formulation. Within a short time, it became the company’s flagship and pioneering product.

2019

BioReHydra^®: Advanced Skin Hydration and Rejuvenation

In 2019 BioReHydra^® was launched, expanding the company’s portfolio with an advanced solution designed to enhance skin hydration and support overall skin rejuvenation.

2020

BioReLift^® and ISO 13485: Innovation and Certified Quality

In 2020 BioReLift^® was introduced to the market, further strengthening the brand’s innovation strategy with a specialized formulation developed to improve skin firmness and promote a visible lifting effect. In the same year our team achieves another crucial milestone: we obtain ISO 13485 certification, attesting to the strength of our corporate commitment.

2021

BioSkin Miami and ISO 22716: International Expansion and Quality

In 2021, the company launched an important phase of international expansion with the opening of BioSkin in Miami, Florida, a U.S.-based operational hub dedicated to the development and expansion of the American market. That year, the company also obtained ISO 22716 certification, further strengthening its commitment to quality, safety, and Good Manufacturing Practices.

2022

ARES^® and WHA-HALAL: HA-Based Mesotherapy Innovation

In 2022, ARES^® was launched, further expanding the company’s portfolio with an innovative mesotherapy solution designed to support advanced aesthetic protocols and enhance treatment performance based on HA. In the same year, the company also obtained WHA-HALAL certification, confirming its commitment to international quality standards and global market accessibility.

2023

Dermo Advance and LUMINESCENS^®: Private Label Growth and Skin Brightening Innovation

In 2023, the company strengthened its business model by establishing Dermo Advance, dedicated to private label development and strategic partnerships, including collaborations with two major Italian pharmaceutical companies. The same year, LUMINESCENS^® was launched: an innovative depigmentation and skin-brightening solution combining a mesotherapy kit with a complementary home-care cream.

2024

CMed Rebranding 2024: A New Corporate Visual Identity

In 2024 a strategic rebranding led to the introduction of the latest corporate logo, marking a new chapter in the company’s visual identity and brand evolution.

2025

CMed Aesthetics Premio Felix: Recognition for Corporate Growth

In 2025 The company’s trajectory has also been recognized through independent awards. CMed Aesthetics received the Premio Felix, awarded for “excellent performance, financial reliability and corporate growth in Central Italy.” This recognition reflects not only economic success but also the company’s ability to generate sustainable and structured growth.

2026

BioReFeel^®: CMed Aesthetics’ First Injectable Product

In 2026 CMed Aesthetics launches its first injectable product on the market, BioReFeel^®, a dermal restructuring filler focused on prejuvenation and revitalization.